Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
Massachusetts General Hospital - Boston, Boston, Massachusetts John Theurer Cancer Center, Hackensack, New Jersey Mount Sinai Tisch Cancer Center, New York, New York NEXT Oncology - Dallas, Dallas, Texas NEXT Oncology - Virginia, Fairfax, Virginia